Moderna And PPD Announce Strategic Collaboration To Support Clinical Development Of Novel mRNATherapeutics
CAMBRIDGE, Mass. & Wilmington, N.C.--(BUSINESS WIRE)--Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced a strategic collaboration to support Moderna’s evolution as a clinical-stage company. Covering a broad expanse of drug modalities and therapeutic areas, Moderna’s pipeline has the potential to address the unmet needs of numerous patients worldwide. PPD will be a key partner in advancing Moderna’s proprietary pipeline as it rapidly scales up its clinical efforts in the coming months and years.